Indeed, by using a surrogate CAR with affinity to murine FLT3, rituximab-mediated depletion of FLT3 CAR T cells after AML eradication enables bone marrow recovery without compromising leukemia remission (101). The gene discussed is FLT3; the disease is leukemia.